| Literature DB >> 32604880 |
Francisca García1,2,3, Pedro Lobos4, Alejandra Ponce1,2,3, Karla Cataldo1,2,3, Daniela Meza1,2,3, Patricio Farías1,2,3, Carolina Estay1,2,3, Felipe Oyarzun-Ampuero5, Rodrigo Herrera-Molina6,7, Andrea Paula-Lima4,8, Álvaro O Ardiles1,9,10, Cecilia Hidalgo4,11,12, Tatiana Adasme7, Pablo Muñoz1,2,3.
Abstract
Astaxanthin (ASX) is a carotenoid pigment with strong antioxidant properties. We have reported previously that ASX protects neurons from the noxious effects of amyloid-β peptide oligomers, which promote excessive mitochondrial reactive oxygen species (mROS) production and induce a sustained increase in cytoplasmic Ca2+ concentration. These properties make ASX a promising therapeutic agent against pathological conditions that entail oxidative and Ca2+ dysregulation. Here, we studied whether ASX protects neurons from N-methyl-D-aspartate (NMDA)-induced excitotoxicity, a noxious process which decreases cellular viability, alters gene expression and promotes excessive mROS production. Incubation of the neuronal cell line SH-SY5Y with NMDA decreased cellular viability and increased mitochondrial superoxide production; pre-incubation with ASX prevented these effects. Additionally, incubation of SH-SY5Y cells with ASX effectively reduced the basal mROS production and prevented hydrogen peroxide-induced cell death. In primary hippocampal neurons, transfected with a genetically encoded cytoplasmic Ca2+ sensor, ASX also prevented the increase in intracellular Ca2+ concentration induced by NMDA. We suggest that, by preventing the noxious mROS and Ca2+ increases that occur under excitotoxic conditions, ASX could be useful as a therapeutic agent in neurodegenerative pathologies that involve alterations in Ca2+ homeostasis and ROS generation.Entities:
Keywords: NMDA; astaxanthin; calcium; excitotoxicity; mitochondrial superoxide
Mesh:
Substances:
Year: 2020 PMID: 32604880 PMCID: PMC7345213 DOI: 10.3390/md18060335
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Cell viability and Ca2+ levels induced by N-methyl-D aspartate (NMDA) addition to SH-SY5Y cells. (A) Representative immunofluorescence images showing the presence of the NMDA glutamate receptor (NMDAR) subunit GluR1/N1. Cells were fixed, permeabilized and incubated with a specific antibody against the GluR1/N1 subunit of the NMDAR (green). The nucleus was stained with Hoescht (blue). The phase-contrast image at the lower right presents the 10 µM calibration bar. (B) Quantification of cell viability evaluated 24 h after treatment for 120 min with 200 µM NMDA. Additionally, cells were pre-incubated for 1 h with 200 µM D-2-Amino-5-phosphonovaleric acid (APV), an NMDA receptor antagonist. The graph shows the % cell viability. The black, red and white bars correspond to unstimulated cells, to cells stimulated with NMDA or to cells stimulated with NMDA in the presence of APV, respectively; the * indicates significant difference (p < 0.05) compared to control: # compared to 200 µM NMDA plus 200 µMAPV. (C) NMDA-induced Ca2+ signals in SH-SY5Y cells loaded with Fluo-4 and treated with 16 µM or 200 µM NMDA. Data were normalized against the fluorescence values obtained before NMDA addition (∆F/F0); *: p < 0.05 compared to 16 µM NMDA. (D) Ca2+ levels detected one minute after addition of 200 µM NMDA, or after addition of 200 µM NMDA to cells pre-incubated for 1 h with 200 µM APV; #: p < 0.05 compared to NMDA-treated cells.
Figure 2Effect of ASX on SH-SY5Y cell metabolic activity. (A) Cells were preincubated for 24 h with vehicle (closed symbols) or with 10 µM ASX (open symbols); following this period, cells were incubated with 16 µM NMDA (green symbols) or 200 µM NMDA (red symbols) for up to 2 h, as indicated in Figure 2A. Cellular metabolic activity was determined 24 h after incubation with NMDA using the MTT assay. #: p < 0.05 when comparing 200 µM NMDA with 200 µM NMDA + ASX. (B) Cells were pretreated with vehicle or 10 µM ASX for 24 h; following this period 50 µM H2O2 was added for 1 h and cellular metabolic activity was measured 24 h later using the MTT assay. *: p < 0.05 compared to vehicle.
Figure 3Mitochondrial Superoxide detection. (A) Reaction scheme of the mitochondrial superoxide sensor and its adduct. SH-SY5Y cells were simultaneously loaded with MitoSOX (red color, B), Mitotracker green (green color, C) and Hoescht (blue color, D). The composite image for MitoSOX, Mitotracker green and the Hoescht stain is shown in panel E. The pixel intensity analysis for the red v/s the green label and for the red v/s the blue label is shown in panels F and G, respectively.
Figure 4Protective effects of ASX on NMDA-induced mitochondrial superoxide generation in SH-SY5Y cells. (A) Mitochondrial superoxide levels were detected as a function of time with the MitoSOX probe following addition of 16 µM or 200 µM NMDA. Data were normalized against the fluorescence values obtained before NMDA addition (∆F/F0). *: p < 0.05 compared to addition of 16 µM NMDA. (B) Mitochondrial superoxide levels were measured one minute after addition of 200 µM NMDA to control cells or to cells preincubated for 60 min with 200 µM APV. #: p < 0.05 compared to NMDA. (C) Cells pretreated with increasing concentrations of ASX (from 0.5 nM to 10 µM) for 24 h were incubated with 200 µM NMDA. #: p < 0.05 compared to 200 µM NMDA in the absence of ASX.
Figure 5Effects of ASX on NMDA-induced calcium signal generation in primary hippocampal neurons. (A) Representative confocal image of a hippocampal neuron (7 DIV) transfected with the genetically encoded calcium sensor GCamP3-actin; the image was collected at the peak of the fluorescence increase induced by 200 µM NMDA. Calibration bar: 40 nm. (B) Representative confocal image of a neuron cultured in similar conditions as in A, except that the culture was pre-incubated for 24 h with 10 µM ASX prior to addition of 200 µM NMDA. Representative line scan images generated by collecting every 1-s from the dendritic region indicated by the red line drawn in the control image (A1) or in the image of ASX-pretreated neuron (B1); the addition of 200 µM NMDA and of 100 µM Ionomycin (IONO) is indicated by a dotted black line. (C). Data were normalized against the fluorescence values obtained before NMDA addition (∆F/F0). The graph shows the fluorescence intensity as a function of time collected from the neuronal control (n = 7; 32 ROIs) and from neuronal cells pretreated with ASX (n = 5; 34 ROIs), before and after addition of 200 µM NMDA. The results are expressed as Mean ± standard error. *: p < 0.05 compared to vehicle.